<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517904</url>
  </required_header>
  <id_info>
    <org_study_id>1-2015-0093</org_study_id>
    <nct_id>NCT03517904</nct_id>
  </id_info>
  <brief_title>Comparison of Intravascular Ultrasound-Guided vs. Angiography-guided Angioplasty and Dual-antiplatelet v. Triple-antiplatelet Therapy for Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease (IVUS-DCB)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Prospective, randomized, controlled, multi-center study

        -  A total of 240 subjects with femoropopliteal artery disease will be included according
           to inclusion and exclusion criteria.

        -  Patients will be randomized in a 1:1 manner into IVUS-guided or angiography-guided
           intervention group.

        -  Second 1:1 randomization into dual antiplatelet therapy (aspirin + clopidogrel) or
           triple antiplatelet therapy (aspirin + clopidogrel + cilostazol) is optional

        -  All patients will be treated with drug-coated balloons (In.PACT Admiral) for
           femoropopliteal lesions.

        -  Bare metal self-expandable stents will be used in addition according to findings of IVUS
           or angiography such as severity of arterial dissection or residual stenosis.

        -  Patients will be followed clinically for 1 year after the procedure.

        -  Ankle-brachial index and Image study follow-up (Duplex US or CT angiography) will be
           performed at 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedures lesion stenosis degree</measure>
    <time_frame>at 12 months</time_frame>
    <description>Absence of restenosis &gt;50% by Duplex ultrasound, CT angiography, or catheter-based angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival free from target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Survival free from repeat intervention or surgical treatment due to loss of patency at the target vessel</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Femoropopliteal Artery Disease</condition>
  <arm_group>
    <arm_group_label>IVUS-guided group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravascular ultrasound-guided intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guided group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Angiography-guided intervention group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVUS-guided angioplasty</intervention_name>
    <description>Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.</description>
    <arm_group_label>IVUS-guided group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiography-guided angioplasty</intervention_name>
    <description>Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.</description>
    <arm_group_label>Angiography-guided group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 years or older

          -  Symptomatic peripheral artery disease:

               -  Moderate or severe claudication (Rutherford category 2 or 3)

               -  Critical limb ischemia (Rutherford category 4 or 5)

          -  Femoropopliteal artery disease (stenosis &gt; 50%)

          -  ABI &lt;0.9

          -  Patients with signed informed consent

        Exclusion Criteria:

          -  Acute critical limb ischemia

          -  Severe critical limb ischemia (Rutherford category 6)

          -  Known hypersensitivity or contraindication to any of the following medications:
             heparin, aspirin, clopidogrel, cilostazol, or contrast agents

          -  Patients requiring oral anticoagulation using warfarin or NOAC

          -  Age &gt; 85 years

          -  Severe hepatic dysfunction (&gt; 3 times normal reference values)

          -  Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding
             diathesis

          -  LVEF &lt; 40% or clinically overt congestive heart failure

          -  Pregnant women or women with potential childbearing

          -  Life expectancy &lt;1 year due to comorbidity

          -  Previous bypass surgery or stenting in the target femoropopliteal artery

          -  Untreated inflow disease of the ipsilateral pelvic or femoropopliteal arteries (more
             than 50% stenosis or occlusion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungGuk Ko, MD</last_name>
      <phone>82-2-2228-8460</phone>
      <email>ygko@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Femoropopliteal artery disease, drug-coated balloon, angioplasty, antiplatelet therapy</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

